Comparable stake leader
Decheng Capital China Life Sciences USD Fund III, L.P.
SEC ownership of ALPINE IMMUNE SCIENCES, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001626199.
Disclosed value leader
Decheng Capital China Life Sciences USD Fund III, L.P.
Comparable rows
0/8
Latest evidence
18 Jan 2024
- Parsed ownership sources
- 3/4/5
- Largest SEC-reported holder
- Decheng Capital China Life Sciences USD Fund III, L.P.
- Latest parsed ownership date
- 18 Jan 2024
- Issuer CIK
- 0001626199
- Issuer location
- Seattle, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ALPINE IMMUNE SCIENCES, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Decheng Capital China Lif...
Disclosed value leader
Decheng Capital China Lif...
Comparable rows
0/8
Latest evidence
18 Jan 2024
3/4/5
Highest disclosed value: $83,859,521
8 rows are not safely comparable across share classes.
Quick read
Decheng Capital China Life Sciences USD Fund III, L.P. has the largest disclosed position value at $83.86M.
0 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Decheng Capital China Life Sciences USD Fund III, L.P.'s linked filing trail.
Disclosed position value
Top 5
Decheng Capital China Life Scienc...
$83.86M
Jay R. Venkatesan
$36.64M
Alpine ImmunoSciences, L.P.
$33.14M
Decheng Capital Global Healthcare...
$22.11M
Frazier Life Sciences VIII, L.P.
$18.91M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$83,859,521
6,582,380 shares
|
— | 18 Jan 2024 |
| Jay R. Venkatesan |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$36,644,978
2,946,372 shares
mixed-class rows
|
— | 15 Jul 2022 |
| Alpine ImmunoSciences, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$33,136,485
2,600,980 shares
|
— | 17 Sep 2021 |
| Decheng Capital Global Healthcare Fund (Master), LP |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$22,110,831
1,735,544 shares
|
— | 09 Nov 2023 |
| Frazier Life Sciences VIII, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$18,907,625
1,484,115 shares
|
— | 11 Feb 2022 |
| Wolfgang Dummer |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
200,000 shares
|
— | 02 Oct 2023 |
| Zelanna Goldberg |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
160,000 shares
|
— | 01 Jun 2021 |
| Andrew Seth Sandler |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
50,000 shares
|
— | 05 Jan 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to ALPINE IMMUNE SCIENCES, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
Decheng Capital China Life Sciences USD Fund III, L.P.
Net 12M change
$0
Latest report
20 May 2024
Recent insider transactions for ALPINE IMMUNE SCIENCES, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.